Determine the Prevalence and Severity of Asthma in HIV (Human Immunodeficiency Virus) Infected Patients
Status: | Completed |
---|---|
Conditions: | Asthma, HIV / AIDS, HIV / AIDS |
Therapuetic Areas: | Immunology / Infectious Diseases, Pulmonary / Respiratory Diseases |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 10/5/2017 |
Start Date: | December 2014 |
End Date: | July 2017 |
HIV and Asthma in the Post-ART (Antiretroviral Therapy) Era
The purpose of this study is to determine the prevalence and severity of asthma in patients
with HIV. To determine the immunological phenotype of HIV-infected patients with asthma.
with HIV. To determine the immunological phenotype of HIV-infected patients with asthma.
Prospectively clinically phenotype and the prevalence of asthma in HIV infected patients in
the Duke ID Clinic
- HIV infected asthmatic subjects meeting clinical definitions for asthma compared to HIV
uninfected asthma subjects identified at the DAAAC and HIV infected non-asthmatic
subjects.
- Prospective immunological phenotyping - HIV-infected asthma subjects prospectively
identified and clinically phenotyped compared to HIV-uninfected asthma subjects
identified at the DAAAC and HIV infected non-asthma subjects.
Regarding the sampling method of probability sample: All samples for HIV infected asthmatic
patients, HIV uninfected asthmatic patients and HIV infected non-asthmatics patients will be
analyzed.
Retrospectively determine overall asthma prevalence and severity among HIV-infected patients.
Retrospective immunological phenotyping (circulating cytokines) of HIV-infected patients
utilizing available specimens in the Duke HIV Specimen Biorepository
- HIV-infected asthmatic subjects meeting asthma definition compared to overall asthma
prevalence in U.S. population
- HIV-infected asthma subjects meeting asthma definitions compared to matched HIV-infected
non-asthma subjects
the Duke ID Clinic
- HIV infected asthmatic subjects meeting clinical definitions for asthma compared to HIV
uninfected asthma subjects identified at the DAAAC and HIV infected non-asthmatic
subjects.
- Prospective immunological phenotyping - HIV-infected asthma subjects prospectively
identified and clinically phenotyped compared to HIV-uninfected asthma subjects
identified at the DAAAC and HIV infected non-asthma subjects.
Regarding the sampling method of probability sample: All samples for HIV infected asthmatic
patients, HIV uninfected asthmatic patients and HIV infected non-asthmatics patients will be
analyzed.
Retrospectively determine overall asthma prevalence and severity among HIV-infected patients.
Retrospective immunological phenotyping (circulating cytokines) of HIV-infected patients
utilizing available specimens in the Duke HIV Specimen Biorepository
- HIV-infected asthmatic subjects meeting asthma definition compared to overall asthma
prevalence in U.S. population
- HIV-infected asthma subjects meeting asthma definitions compared to matched HIV-infected
non-asthma subjects
Inclusion Criteria:
- HIV infected asthmatic and non-asthmatic adults ≥18 years
- HIV uninfected asthma adults ≥18 years
- Females of childbearing potential have to be using medically acceptable contraceptive
method for the duration of the study.
- Willing and able to give informed consent and adhere to visit/protocol schedules.
- Negative pregnancy test in women of childbearing potential
- For asthma patients: known or possible diagnosis of asthma for at least one year
Exclusion Criteria:
- Antibiotic administration for upper respiratory infection within the prior 30 days
- Greater than 10 pack a year smoking history
- No prior use of steroids (systemic) within the past 3 months
- Underlying illnesses that may result in altered lung function
- Students or employees who are under direct supervision of any Project or Core
PI/Director.
- Pregnant or nursing mothers.
- Poorly controlled concomitant conditions as determined by the investigator.
- Subjects who have had an elective procedure (for example, colonoscopy, cystoscopy,
etc.) within less than 2 weeks of the procedure date cannot be enrolled in the HIV
Asthma study
- Subjects must delay enrollment by 2 weeks into the HIV Asthma study if they have
received a single dose of systemic steroids
We found this trial at
1
site
Durham, North Carolina 27704
Principal Investigator: Loretta Que, M.D.
Click here to add this to my saved trials